Orvepitant maleate
- Product NameOrvepitant maleate
- CAS579475-24-4
- CBNumberCB83146347
- MFC35H39F7N4O6
- MW744.6961824
- MDL NumberMFCD20926416
- MOL File579475-24-4.mol
Chemical Properties
| solubility | Acetonitrile: Slightly Soluble: 0.1-1 mg/ml Chloroform: Slightly Soluble: 0.1-1 mg/ml |
| form | Solid |
| color | Off-white to light yellow |
Orvepitant maleate Chemical Properties,Usage,Production
Uses
Orvepitant maleate (GW823296 maleate) is potent, selective, orally active and well-tolerated neurokinin-1 receptor (NK-1) antagonist with a pKi of 10.2 for human neurokinin-1 receptor. Orvepitant maleate can across the blood-brain barrier. Orvepitant maleate has the potential for depressive disorder and chronic refractory cough (CRC) treatment[1][2].in vivo
Orvepitant (Compound 3a; 0.3-10 mg/kg; Oral administration; marmoset) treatment shows a dose dependant reduction of the number of postures was observed at 1 mg/kg (34.9% reduction), 3 mg/kg (36.6% reduction) and 10 mg/kg (46.4% reduction), suggesting a potential anxiolytic-like effect of the compound[1].
Orvepitant (compound 3a) shows an oral bioavailability (F) of 17% in rat and 55% in dog, plasma clearance (Clp) of 29 mL/min/kg in rat and 6 mL/min/kg in dog and a half-life of 2.3 h in rat and 6.1 h in dog. As far as the brain penetration in rats is concerned, a B/P ratio of 1.2 is observed 5 min after the i.v. administration of a 1 mg/kg dose of Orvepitant[1].
| Animal Model: | Human threat test in the marmoset (HTT)[1] |
| Dosage: | 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg |
| Administration: | Oral administration |
| Result: | A dose dependant reduction of the number of postures was observed at 1 mg/kg (34.9% reduction), 3 mg/kg (36.6% reduction) and 10 mg/kg (46.4% reduction). |
IC 50
NK1: 10.2 (pKi)References
[1] Di Fabio R, et al. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate. Bioorg Med Chem. 2013 Nov 1;21(21):6264-73. DOI:10.1016/j.bmc.2013.09.001[2] Smith J, et al. The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1). Chest. 2020 Jan;157(1):111-118. DOI:10.1016/j.chest.2019.08.001
[3] MICHAEL K. TROWER. Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour[J]. Experimental Dermatology, 2014, 23 11: 858-860. DOI: 10.1111/exd.12528
Orvepitant maleate Suppliers
Global(13)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | 32430 | 58 | ||
| tp@aladdinsci.com | 50039 | 58 | |||
| +86-027-59232304 15387063101 | 1276242629@qq.com | 9997 | 58 | ||
| 18171815831 | 1341138380@qq.com | 4647 | 58 | ||
| 021-65675885 18964387627 | info@efebio.com | 9799 | 58 | ||
| 021-52996696,15000506266 15000506266 | 4871 | 55 | |||
| +86-0571-86912261 +86-15658003402 | sales@newcanbio.com | 2135 | 58 | ||
| 4008200310 15002144251 | marketing@tsbiochem.com | 24951 | 58 | ||
| 1-631-485-4226; 16314854226 | info@bocsci.com | 9920 | 65 | ||
| 51288865780 | sales@biosynth.com | 6031 | 58 |